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One Sentence Summary: Non-invasive mutation tracking in plasma can detect 
circulating tumor DNA arising from residual micro-metastatic disease and thus 
identify patients at high-risk of recurrence.  
 
Abstract  
The identification of early stage breast cancer patients at high risk of relapse would 
allow tailoring of adjuvant therapy approaches. We assessed whether analysis of 
circulating tumor DNA (ctDNA) in plasma can be used to monitor for minimal 
residual disease (MRD) in breast cancer. In a prospective cohort of 55 early breast 
cancer patients receiving neoadjuvant chemotherapy, detection of ctDNA in plasma 
after completion of apparently curative treatment—either at a single post-surgical 
time-point or with serial follow-up plasma samples—predicted metastatic relapse with 
high accuracy (hazard ratio 25.1, CI 4.08-130.5, log rank P < 0.0001; or hazard ratio 
12.0, CI 3.36-43.07, log rank P < 0.0001, respectively). Mutation tracking in serial 
samples increased sensitivity for prediction of relapse, with a median lead-time of 7.9 
months over clinical relapse. We further demonstrated that targeted capture 
sequencing analysis of ctDNA could define the genetic events of MRD, and that 
MRD sequencing predicted the genetic events of the subsequent metastatic relapse 
more accurately than sequencing of the primary cancer. Mutation tracking can 
therefore identify early breast cancer patients at high risk of relapse. Subsequent 
adjuvant therapeutic interventions could be tailored to the genetic events present in 
the MRD, a therapeutic approach that could in part combat the challenge posed by 




Breast cancer is the most frequently diagnosed cancer worldwide and in women the 
second most common cause of cancer deaths (1). Approximately 95% of women with 
breast cancer present with early stage cancer without macroscopic evidence of 
metastases (2). In many women, however, breast cancer has already metastasized at 
diagnosis and such micro-metastatic disease can, in time, result in overt metastatic 
recurrence. The identification of those patients who have residual micro-metastatic 
disease, or minimal residual disease (MRD), that has not been eradicated by adjuvant 
systemic therapy and surgery, would allow for the development of clinical trials of 
adjuvant therapies to prevent relapse focused on those who are at highest risk. 
Circulating tumor-derived DNA (ctDNA) can be detected in the plasma and 
serum of patients with advanced cancer (3), acting as a potential non-invasive source 
to characterize the somatic genetic features of their tumors (4-7). Limited data are 
available on whether ctDNA analyses would be applicable to early cancer (8, 9), in 
part because the low tumor burden of micro-metastatic disease makes detection of 
ctDNA challenging, as ctDNA is often detectable at a very low level in plasma DNA 
(10, 11)  
Here we assess the potential to detect ctDNA in early-stage, primary breast 
cancer. We demonstrate that ctDNA detection with personalized digital PCR (dPCR) 
assays of somatic mutations, can be used to identify MRD, and that such MRD 
detection with plasma ctDNA can accurately identify patients at risk of cancer relapse. 
After detection of patient ctDNA with dPCR mutation tracking, we further asked 
whether high-depth targeted MPS of ctDNA could be used to interrogate the genetics 





Personalized tumor-specific digital PCR assays for mutation tracking  
We investigated the potential utility of ctDNA analysis in early breast cancer in a 
prospectively accrued cohort of 55 women presenting with early stage breast cancer 
who received neoadjuvant chemotherapy followed by surgery (Fig. 1). We subjected 
primary tumor DNA, extracted from a tumor biopsy at diagnosis prior to treatment, to 
MPS, identifying one or more somatic mutation(s) in 78% (43/55, 95% CI 65%-88%) 
of cancers, with two or more mutations found in 12 cases.  
To track these mutations in plasma DNA and identify the presence of ctDNA, 
we designed personalized dPCR assays for each somatic mutation identified (table 
S1). dPCR can accurately quantify mutant DNA at single-molecule sensitivity, even 
in the presence of vast amounts of wild-type DNA (Fig. 1) (12, 13). MPS and dPCR 
analysis had a high level of agreement in baseline tumor DNA in the assessment of 
the mutant allele fractions (Fig. 2A), demonstrating the robust ability to develop 
dPCR assays for diverse mutations. For a representative number of cases (n = 9), 
estimation of mutation frequency in plasma DNA was highly correlated in replicate 
dPCR assays (r2 = 0.98) (Fig. 2B). In patients with two mutations identified in the 
primary tumor, we tracked both mutations in plasma with 96% agreement for 
present/absent mutation-calling in the same plasma DNA sample (κ = 0.92; 95% CI 
0.77-1.0), emphasizing the reproducible and robust nature of the assays developed. 
 
Tracking mutations in ctDNA to identify MRD and anticipate relapse 
We next assessed whether dPCR could be employed for the detection of ctDNA to 
predict early relapse. The personalized dPCR assays were used to track mutations in 
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serial plasma samples taken at baseline, post-operatively with the sample taken 2-4 
weeks after surgery, and then every 6 months during follow-up (Fig. 2C, fig. S1). 
Two patients whose tumors harbored the same PIK3CA c.3140A>T (p.H1047L) 
somatic mutation illustrated the potential of mutation tracking. In A310001, who 
remained disease-free at 30 months post-surgical follow-up, the mutation was 
undetected in all follow-up plasma samples, suggesting clearance of tumor by 
neoadjuvant chemotherapy and surgery. In contrast, in A310006 ctDNA was detected 
in the post-surgery sample, identifying the presence of MRD. At 6.2 months post-
surgery there was a dramatic increase in mutation abundance, suggesting increasing 
disease burden, followed by clinical relapse 8.1 months post-surgery with widespread 
metastatic disease.  
We assessed the potential to predict relapse from the different time points of 
ctDNA analysis, starting with the baseline plasma sample taken at diagnosis before 
any treatment. Consistent with previous observations (9), ctDNA was detected in 69% 
(29/42, 95% CI 53%-82%) of baseline plasma samples (Fig. 3). The level of baseline 
ctDNA was associated with markers of disease aggressiveness, such as histological 
grade and estrogen receptor (ER)–negative status, but not primary tumor size (table 
S2). ctDNA detection at baseline, prior to any treatment, was not predictive of 
disease-free survival (Fig. 3A), and ctDNA abundance at baseline was not statistically 
associated with early relapse (median 13.8 vs. 3.13 mutations per ml for early relapse 
and disease-free survival, respectively) (Fig. 3B).  
 We next assessed the potential of a single post-surgical sample taken 2-4 
weeks after surgery. ctDNA was detected in the single post-operative blood test in 
19% (7/37, 95% CI 8-35%) of patients (Fig. 4A), with highly variable mutational load 
(median of 19.2 copies/ml, range 1.8 to 6284 copies/ml). In these samples, ctDNA 
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detection was predictive of early relapse (disease-free survival ctDNA detected 
median 6.5 months vs not-detected median not reached, HR 25.1, 95% CI 4.08-130.5) 
(Fig. 4A), with a C-index of 0.78. Detection of ctDNA in single post-surgical sample 
was a significant predictor of early relapse in a multivariable model (table S3). Six 
patients did not have a sample taken at the 2-4 week post-surgery time-point and were 
excluded from analysis of this time-point. 
 We examined whether the detection of ctDNA in serial samples, which we 
termed “mutation tracking”, could improve relapse prediction compared with a single 
post-surgery sample (Fig. 4B). Detection of ctDNA in serial samples was predictive 
of early relapse (disease-free survival ctDNA detected median 13.6 months vs not-
detected median not reached, HR 12.0, 95% CI 3.36-43.07), with a C-index of 0.75. 
Detection of ctDNA by mutation tracking was a significant predictor of early relapse 
in a multivariable model (table S4).  
Sensitivity in a single post-surgical sample was limited by patients who had 
undetectable ctDNA in the single post-surgical plasma sample and required serial 
sampling to detect ctDNA. Of the patients who relapsed in the follow-up period, 50% 
(6/12) had ctDNA detected in the single post-surgical sample and 80% (12/15) had 
ctDNA detected by mutation tracking. Of the patients who did not relapse, 96% did 
not have ctDNA detected in either the single post-surgical sample (24/25) or by 
mutation-tracking (27/28) (P = 0.0038 for single post-surgical sample; P < 0.0001 for 
mutation tracking in serial samples, Chi Square test with Yates’ correction). One 
patient with ctDNA detectable post-surgery did not relapse in the follow-up period 
(A310033) (Fig. 5A). This patient with triple-negative breast cancer had ctDNA 
detectable in the first post-surgery sample, with a subsequent increase in ctDNA 
abundance in serial sampling. 
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Detection of ctDNA had a median 7.9 months (range 0.03-13.6 months) lead 
time over clinical relapse, identifying the presence of MRD that was not detectable on 
conventional imaging for patient A310004 (Fig. 5B). ctDNA did not disappear in 
serial sampling of plasma from patients with early relapse (Fig. 5C). Both assessment 
of ctDNA in the single post-operative sample and mutation-tracking in serial samples 
appeared to predict relapse in all the major subtypes of breast cancer (Fig. 6), 
although mutation-tracking with serial samples was more sensitive in ER+ breast 
cancer.   
In the three patients whose metastatic relapse was restricted to the brain, no 
ctDNA was detectable by dPCR prior to or at relapse. Patients with gliomas 
frequently have undetectable ctDNA (9), suggesting that the detection of recurrences 
restricted to the brain may be challenging by means of mutation-tracking. In contrast, 
extra-cranial MRD was predicted by ctDNA mutation tracking in all patients who 
relapsed (n=12) (p=0.0022, Chi square test with Yates’ correction). 
 
Genomic characterization of MRD by high-depth plasma DNA sequencing 
Intra-tumor genetic heterogeneity is found in many solid tumors, including breast 
cancer (14-16). Adjuvant therapies targeted at the genetic characteristics of the 
primary cancer may be ineffective if micro-metastatic disease displays different 
genetic alterations to those found in the primary cancer. Having demonstrated that 
mutation tracking can anticipate clinical relapse, we set out to establish if high-depth 
targeted capture MPS of plasma DNA could be employed to interrogate the genetic 
profile of MRD prior to relapse, and in cancers with intra-tumor genetic heterogeneity 
assess whether the genetic profile of MRD reflected that of the original primary breast 
cancer or the subsequent metastatic recurrence. 
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Once mutation tracking had confirmed the presence of MRD, we sequenced 
DNA from the primary cancer, from residual primary tumor post-chemotherapy 
removed at surgery, from plasma DNA taken prior to relapse, and from the 
subsequent metastasis when biopsied, in 5 patients with a panel targeting all exons of 
273 genes recurrently mutated in breast cancer (17). The sequencing strategy was 
optimized for low DNA inputs using hybrid capture with a custom NimbleGen 
SeqCap EZ Choice library followed by sequencing on a HiSeq2000 to a mean target 
depth after duplicate removal of 460x (range 104x-1015x). In all 5 cases, we 
identified tumor-specific mutations by high-depth sequencing of the plasma DNA 
taken prior to clinical relapse, demonstrating its widespread applicability in 
interrogating the genetics of MRD (Fig. 7 and fig S2). Targeted capture MPS also 
revealed copy number alterations in the plasma samples of two patients, consistent 
with those documented in the primary tumor and/ or metastatic relapse (fig. S3). Copy 
number alterations where not identifiable in the remaining cases, likely as ctDNA was 
present a small fraction of total plasma DNA.  
 We next addressed whether the repertoire of somatic genetic alterations 
identified in the analysis of ctDNA arising from MRD would merely recapitulate that 
of the original primary cancer, or reveal greater diversity reflective of intra-tumoral 
genetic heterogeneity. In one case, A310006, ctDNA sequencing by MPS revealed no 
additional genetic events to the PIK3CA mutation found in the primary cancer (using 
AmpliSeq PGM, as there was insufficient DNA for capture sequencing), suggesting 
homogeneity in the genetics of the MRD for this patient (fig. S2). However, in all 
other patients we uncovered diversity in the genetics of MRD compared to the 
primary cancer (Fig. 7 and fig S2). For example, plasma DNA sequencing revealed 
 8 
substantial divergence of the genetics of the ctDNA arising from RMD compared to 
the original primary tumor for patient A310012 (fig. S2). 
In patient A310003, sequencing of ctDNA revealed the presence of a PIK3CA 
mutation present in both the primary and metastatic lesion; however, the repertoire of 
somatic mutations found in the plasma (ctDNA arising from MRD) was more similar 
to that of the subsequently biopsied metastatic relapse than that of the primary cancer 
(Fig. 7A). In particular, ctDNA sequencing identified an activating FGFR1 K656E 
mutation that was not present in the analyzed primary tumor biopsy but was present in 
the metastasis (Fig. 7A). The FGFR1 K656E mutation is directly paralogous to the 
FGFR3 K650E activating mutation that is frequently found in bladder cancer and in 
thanatophoric dysplasia type II (18, 19). Similarly, ctDNA sequencing identified loss 
of an ESR1 E380Q mutation found in the primary, but not in the metastasis, 
anticipating loss of estrogen receptor in the metastasis, which was confirmed by 
immunohistochemistry (fig. S4A). Sequencing of two foci of residual primary tumor 
post-chemotherapy provided evidence of consistent clonal selection compared to the 
primary tumor prior to treatment, although the changes did not predict those that were 
found in the subsequent metastasis (Fig. 7A). When tracked by dPCR, the primary 
tumor PIK3CA mutation remained present in plasma DNA and metastasis, indicating 
an early clonal event in the cancer.   
 In patient A310035, sequencing ctDNA prior to relapse predicted 
acquisition of a SYNE1 S1244Y mutation in the subsequently biopsied metastasis, as 
well as enrichment for a GATA3 frameshift mutation and loss of a STAT3 mutation 
(Fig. 7B). In this patient, enrichment for the SYNE1 mutation was demonstrated in the 
residual tumor post chemotherapy (fig. S4B). Last, in patient A310004, sequencing of 
the relapsed tumor revealed an RB1 R320* somatic mutation that was not detectable 
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by sequencing of the plasma ctDNA taken 8.1 months prior to relapse (13 months 
post-surgery) (Fig. 7C). We developed and optimized a multiplex dPCR assay (fig. 
S4C) to track this mutation, along with the other two mutations in ANK3 and XIRP2 
that were present in both the primary and recurrence in this patient. dPCR 
demonstrated that the RB1 mutation was a late event, only first detectable in a plasma 
sample taken 16.1 months post-surgery, then expanding in frequency on serial 
sampling at relapse (Fig. 7C). This suggests that genetic diversity develops in 
expanding micro-metastatic disease prior to relapse, and that mutation-tracking may 
have the potential to identify MRD at a point before genetic diversity develops. 
 
Discussion 
Here we show that circulating tumor DNA mutation tracking can detect MRD non-
invasively and identify earlier which patients are at risk of cancer recurrence. We 
devised an assay pipeline that uses baseline primary tumor mutations to develop 
personalized dPCR assays to track the presence of ctDNA in plasma over time. After 
using dPCR to detect MRD, we showed that high-depth plasma DNA sequencing can 
help define the repertoire of somatic genetic alterations found in MRD, providing 
evidence of clonal shifts in response to systemic therapy.  
Our data illustrate fundamental principles for the use of ctDNA in the 
detection of MRD. Driver, and likely clonal, mutations should be tracked in 
preference to sub-clonal non-driver mutations, which may be lost in the MRD that 
subsequently repopulates the metastatic recurrence (A310003, A310035, A310012). 
In our study, serial sampling during follow-up was required for accurate MRD 
detection and relapse prediction. Our data suggest that the burden of MRD at a single 
post-surgical time-point soon after completing neoadjuvant chemotherapy is, in some 
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cases, insufficient for its detection in the plasma DNA; or, owing to lack of 
proliferation and apoptosis in the MRD, there is no release of ctDNA. These findings 
contrast with a report where ctDNA detection with BEAMing in a single colorectal 
cancer sample taken after surgical resection of liver metastases offered high predictive 
potential, potentially due to the high burden of micro-metastatic disease in this setting 
(10). Nevertheless, we recommend serial sampling to detect the MRD as it 
proliferates and expands. Mutation tracking in serial samples may be particularly 
important in ER-positive breast cancer, to detect ctDNA changes during post-
operative endocrine therapy (Figure 6).  
We used digital PCR to assay plasma samples in this study. This relatively 
cost-efficient technology represents, along with BEAMing, the most sensitive 
techniques currently available for detection of known rare mutations. Alternative 
techniques include the detection of structural variants (11), although the challenge in 
advancing this technique to clinical practice is accurate identification of these variants. 
MPS of plasma is challenged by polymerase error in detecting rare variants, although 
techniques such as barcoding for error correction (20) may allow MPS to challenge 
dPCR for sensitivity. Nevertheless, no other technologies have been capable of 
quantifying ctDNA for early detection of minimal residual disease 
 Intra-tumor genetic heterogeneity reflecting clonal diversity in cancers (14-16) 
presents a potential major barrier for successful adjuvant therapy that aims to 
eradicate micro-metastatic disease and prevent recurrence (21). Adjuvant therapies 
targeted at the genetic characteristics of the primary cancer may be ineffective if 
micro-metastatic disease displays different genetic alterations to those found in the 
primary cancer. Here we show that high-depth targeted capture MPS of ctDNA prior 
to relapse has the potential to address this challenge by interrogating the genetic 
 11 
characteristics of MRD to identify the lethal clone that may differ in its repertoire of 
somatic mutations from the dominant clone in the primary cancer. We detected 
potentially targetable mutations in the ctDNA that were not in the primary tumor; in 
some cases, other targetable mutations were lost from primary tumor to ctDNA. 
Resistance mutations can be detected in plasma many months prior to the 
development of clinical resistance in the metastatic setting (22, 23) and we 
demonstrated that this concept can be extended to patients with potential curable 
micro-metastatic disease.  
 Targeted therapy has the potential to cure patients in the adjuvant setting with 
micro-metastatic cancer (24), likely owing to the low disease burden, whereas 
targeted therapy is almost uniformly unable to cure patients with advanced metastatic 
disease (25). We demonstrate that the micro-metastatic disease may evolve over time, 
with late appearance of a RB1 mutation that might cause resistance to targeted therapy 
with CDK4/6 inhibitors. This suggests that the approach described here may lead to 
the detection of MRD prior to the establishment of genetic diversity. 
 Despite our encouraging findings for improving early treatment of breast 
cancer patients, the follow-up was short (~2 years), with relatively few patients. 
Sequencing of the plasma DNA taken at relapse, with the capture 273-gene panel, to 
752x depth in one patient with a brain metastasis revealed no detectable mutations. 
The lack of sensitivity for the detection of metastatic disease restricted to the brain 
likely suggests that the blood–brain barrier blocks the release of ctDNA into 
circulation. We were unable to address the potential ctDNA detection in patients who 
have had primary surgery and no chemotherapy, as our study focused on the ability to 
detect MRD after neoadjuvant chemotherapy and surgery. In addition, as patients in 
this series did not have regular imaging studies in the follow-up, a future prospective 
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study comparing with imaging is required.  Our results could potentially be extended 
by tracking a large number of mutations in each blood sample, in part by greatly 
extending the targeted sequencing panel to identify multiple mutations in each patient. 
The theoretical potential for loss of individual driver mutations in metastatic disease 
could be countered by such an approach, although that is not observed in our series. 
However, in our study, assaying for three clonal mutations in the post-surgery sample 
from patient A310004 was unable to detect ctDNA. This suggests that a substantial 
increase in the number of genetic events tracked per milliliter of plasma would be 
required. 
 In conclusion, we have shown that non-invasive mutation tracking in plasma 
DNA can detect residual micro-metastatic disease, or MRD, which standard treatment 
has failed to eradicate, and thus identify patients at high-risk of recurrence. 
Furthermore, we have shown that the genetic events of metastatic disease may differ 
from those found in the primary tumor. This knowledge will allow for therapeutic 
interventions tailored to the driver genetic events present in micro-metastases in a 





Serial plasma samples were collected from patients with early breast cancer to assess 
the potential of assays of ctDNA to predict relapse following treatment. Patients (table 
S5) were recruited from the Royal Marsden Hospital and were treated with standard 
therapy. Tumor DNA was extracted from the baseline pretreatment tumor biopsy, and 
sequenced with an amplicon PGM library to identify mutations specific to the tumor. 
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Digital PCR assays specific to that mutation were developed to track the mutation on 
circulating tumor DNA, at baseline, and in sequential plasma samples taken post-
operatively. The log rank test was used to assess the association between detection of 
ctDNA and disease free survival (DFS).  
 
Patient Cohort and Sample Collection 
Fifty-five patients scheduled to receive neoadjuvant chemotherapy were analyzed 
from prospective sample collection studies, the ChemoNEAR study (REC Ref No: 
11/EE/0063) or the Plasma DNA study (REC Ref No: 10/H0805/50) approved by 
Research Ethics committees (East of England – Essex and London – Bromley, 
respectively). Written informed consent was obtained from all participants. Staging 
investigations were performed at baseline for all node positive and/or cT3/4 patients 
with CT scan and bone scans, and those with distant metastatic disease were excluded 
from the study. Patients were treated with standard neoadjuvant chemotherapy 
(sequential anthracyclines-taxane based chemotherapy in 51 patients, sequential 
anthracyclines-paclitaxel + carboplatin in 2 patients and docetaxel + 
cyclophosphamide in 2 patients) with/without trastuzumab depending of HER2 status. 
After completion of surgery, with or without radiotherapy, patients were treated with 
adjuvant hormone therapy or trastuzumab as per standard local practice, and followed 
up in a nurse-led open access follow-up programme. In the series a single patient 
presented with axillary lymphadenopathy from a cryptic breast primary. This patient 
had radiotherapy to the breast, axillary and supraclavicular nodes after neoadjuvant 
chemotherapy, without surgery.  
Core biopsies were taken at baseline, at surgery, and where clinically indicated 
at recurrence. Plasma samples were collected into EDTA K2 tubes at baseline (prior 
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to chemotherapy), post-surgery (2-4 weeks post-surgery) and every 6-months in 
follow-up or until relapse, whichever occurred first (Figure 1). Clinicopathological 
characteristics of the study cohort are available in table S5 while a consort flow 
diagram of the patients included in the study is available on figure S5.  Estrogen 
receptor (ER), progesterone receptor (PR), and HER2 status were assessed in a single 
laboratory at the Royal Marsden Histopathology department using standard criteria. 
 
Processing and DNA extraction from tumor samples  
Tissue from core biopsies taken at diagnosis, surgery, and recurrence, were formalin-
fixed and embedded in paraffin (FFPE). Sections (4-8 x 4µm) were stained with 
Nuclear Fast Red (NFR) and micro-dissected under a stereomicroscope to achieve 
>70% tumor cell content. Tumor DNA was isolated using the QIAamp DNA FFPE 
Tissue Kit (Qiagen) as per manufacturer’s instructions. Germline DNA was extracted 
from buffy coat DNA using DNeasy Blood and Tissue kit (Qiagen) as per 
manufacturer instructions. 
 
Processing of plasma and extraction of circulating DNA 
Blood collected in EDTA K2 tubes was processed within two hours of sample 
collection and centrifuged at 1600 rpm for 20 min, with plasma stored at -80°C until 
DNA extraction. DNA was extracted from 2-4 ml of plasma using the QIAamp 
circulating nucleic acid kit (Qiagen) according to the manufacturer’s instructions. The 
DNA was eluted into 50 μl buffer AVE and stored at -20°C. 
 
DNA quantifications from tissue and/or plasma 
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DNA isolated from tissue or plasma was quantified on a Bio-Rad QX-100 droplet 
ddPCR using RNase P as the reference gene. One µl of eluate was added to a digital 
PCR reaction containing 10 µl ddPCR Supermix for probes (Bio-Rad) and 1 µl of 
TaqMan Copy Number Reference Assay, human, RNase P (Life Technologies) on a 
total volume of 20 µl. The reaction was partitioned into ~14,000 droplets per sample 
in a QX-100 droplet generator according to manufacturer’s instructions. Emulsified 
PCR reactions were run on a 96 well plate on a G-Storm GS4 thermal cycler 
incubating the plates at 95°C for 10 min followed by 40 cycles of 95°C for 15 sec and 
60°C for 60 sec, followed by 10 min incubation at 98°C. The temperature ramp 
increment was 2.5°C/sec for all steps. Plates were read on a Bio-Rad QX-100 droplet 
reader using QuantaSoft v1.4.0.99 software from Bio-Rad. At least two negative 
control wells with no DNA were included in every run. The amount of amplifiable 
RNase P DNA was calculated using the Poisson distribution in QuantaSoft. 
 
Assessment of recovery of mutant DNA extracted from plasma 
Genomic DNA (gDNA) was extracted from the PIK3CA mutation c.3140A>T GP2d 
colon adenocarcinoma cell line (European Collection of Cell Cultures (ECACC) Cat 
no: 95090714), with DNeasy Blood and Tissue Kit (Qiagen) as per manufacturer 
instructions. DNA was quantified using Quant-iT PicoGreen dsDNA Assay Kit (Life 
Technologies) as per manufacturer instructions. 5 µg genomic DNA was restriction 
digested using HindIII endonuclease and the concentration of c.3140A>T mutant 
DNA copies was calculated using a digital PCR assay on at least 5 replicates, on the 
QX-100 ddPCR system (Bio-Rad) using the PIK3CA c.3140A>T primers and probes 
described in table S1. A total of 150 copies of the PIK3CA c.3140A>T mutation were 
spiked into 1 ml wild-type (WT) plasma samples and immediately processed as 
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described above. Of the input PIK3CA mutant DNA, 43% 95%CI+-2.2% was 
recovered and analyzed by the digital PCR assay. 
 
Ion PGM sequencing of baseline tumor samples 
Sequencing libraries were prepared with a custom Ion AmpliSeq Breast Cancer Panel 
targeting 14 known breast cancer driver genes (26) (table S6) using the Ion AmpliSeq 
Library Preparation protocol with 5ng tumor DNA, according to manufacturer’s 
instructions. Following barcoding, libraries were quantified using qPCR, diluted to 
100 pM and pooled. Libraries were templated with the Ion PGM template OT2 200 
Kit (Life Technologies), and sequenced on a 318 PGM chip using Ion PGM 
Sequencing 200 Kit v2 (Life Technologies) and 500 flows to a mean depth of x2355. 
The sequencing resulted in 200,000-650,000 reads per sample. Variant caller v4.0-
r73742 with no Hotspot region and configuration “Germ Line Low Stringency” was 
used for calling variants, and variants not reported as germline in dbSNP were 
selected as potentially being somatic mutations. Potential somatic mutations were 
cross-referenced against the 1000 Genomes Project database 
(www.1000genomes.org), and only variants that did not appear on the 1000 genomes 
database where taken forward for development of digital PCR assays. 
 
Hybrid capture MPS 
In five patients who experienced relapse, DNA extracted from microdissected primary 
tumor, residual tumor post-chemotherapy removed at surgery, metastatic tumor 
biopsies where available, plasma DNA samples, and germline lymphocyte DNA to 
exclude germline polymorphisms, was subjected to targeted capture massively 
parallel sequencing. Custom oligonucleotides (Roche NimbleGen SeqCap EZ Choice) 
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were designed for hybridization capture of all protein-coding exons of 273 genes 
recurrently mutated in breast cancer or involved in DNA repair pathways as 
previously described (17, 27). Using 12.5 to 50 ng of DNA, barcoded sequence 
libraries were prepared (NEXTflex barcode adapters, Bioo Scientific), amplified 
(KAPA Biosystems) and 12 barcoded libraries pooled at equimolar concentrations 
into a single exon capture reaction as previously described (17, 27, 28). Paired-end 
75x75bp sequencing was performed on a single lane of an Illumina HiSeq2000 flow 
cell. Sequencing reads were aligned to the reference human genome hg19 using the 
Burrows-Wheeler Aligner (v0.6.2) (29), and local-realignment and base quality 
recalibration were performed using the Genome Analysis Toolkit (GATK) (30). 
Duplicates were removed using SAMtools (31). Somatic single nucleotide variants 
(SNVs) were identified using muTect (32). GATK Haplotype Caller (v3.1.1) (30), 
and Strelka (33). To minimize potential false positive results obtained with high-depth 
targeted massively parallel sequencing performed with DNA extracted from formalin-
fixed, paraffin-embedded tissues, or plasma only SNVs identified by at least two out 
of the three callers employed were considered valid as previously described (17). 
Small insertions and deletions (indels) were identified using GATK Haplotype Caller 
and VarScan2 (v2.3.6) (34), and gene copy number aberrations were generated using 
VarScan2, segmented using circular binary segmentation, and gains and losses called 
using the R package CGHcall. All candidate mutations identified in a given tumor or 
plasma DNA sample were validated manually in all other plasma DNA or tumor 
samples of the given patient, and mutations supported by two or more reads were 
regarded as being present (table S7). 
 
Development of mutation specific digital PCR assays 
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Digital PCR was performed on a QX-100 droplet digital PCR system (Bio-Rad) using 
TaqMan chemistry. For each tumor mutation we designed a primer probe 
combination using Primer 3 plus or Life Technologies’ custom Single Nucleotide 
Polymorphism (SNP) genotyping assays tool (table S1). Primers and probes were 
designed to avoid reported SNPs. Primers and probes were analyzed for the presence 
of hairpins, secondary structures or hetero/homo dimers formation. Primers were 
analyzed for specificity using University of California, Santa Cruz ePCR tool 
(http://genome.ucsc.edu/cgi-bin/hgPcr?command=start). Digital PCR conditions were 
optimized with a temperature gradient to identify the optimal annealing temperature 
using either a wild type DNA spiked with a mutant synthetic oligonucleotide, or cell 
line DNA known to carry the mutation. Following optimization, the baseline tumor 
DNA sample was analyzed to validate the assay. The complete absence of mutation in 
the corresponding patients germline lymphocyte DNA, and unmatched plasma 
samples from metastatic breast cancer patients, was confirmed by dPCR. 
 
Digital PCR analysis of circulating free plasma DNA 
Digital PCR was performed on a QX-100 ddPCR system (Bio-Rad) using TaqMan 
chemistry with primers and probes described in table S1 at a final concentration of 
900 nM primers and 250 nM probes. PCR reactions were prepared with ddPCR 
Supermix for probes (Bio-Rad) and partitioned into a median of 50,000 droplets per 
sample in a QX-100 droplet generator according to manufacturer’s instructions. DNA 
extracted from 4 ml of plasma was analyzed for the presence of the mutation at each 
timepoint. Emulsified PCR reactions were run on a 96 well plate on a G-Storm GS4 
thermal cycler incubating the plates at 95°C for 10 min followed by 40 cycles of 95°C 
for 15 sec and specific assay extension temperature (table S1) for 60 sec, followed by 
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10 min incubation at 98°C. The temperature ramp increment was 2.5°C/sec for all 
steps. Plates were read on a Bio-Rad QX-100 droplet reader using QuantaSoft 
v1.4.0.99 software from Bio-Rad to assess the number of droplets positive for mutant 
DNA, wild type DNA, both or neither. At least two negative control wells with no 
DNA were included in every run.  
 
Digital PCR analysis  
To assess mutation fraction, the concentration of mutant DNA (copies of mutant DNA 
per droplet) was estimated from the Poisson distribution. Number of mutant copies 
per droplet Mmu = -ln (1-(nmu/n)), where nmu = number of droplets positive for 
mutant-FAM probe and n = total number of droplets. The DNA concentration in the 
reaction was estimated as follows MDNAconc = -ln (1-(nDNAcon/n)), where 
nDNAconc = number of droplets positive for mutant-FAM probe and/or Wild Type-
VIC probe and n = total number of droplets. The Fraction Mutation = Mmu/ 
MDNAconc.  
To assess the number of mutant copies per ml of plasma, the number of 
mutant-FAM positive droplets was adjusted for the number of wells run for the 
sample, the total number of droplets generated, the median volume of a droplet (0.89 
pl), and volume equivalent of plasma run, using the following formula:  
 
Mutant copies per ml = (Total number of droplets positive for FAM) x 20,000 x 




A mutation was only considered to be present if two or more FAM positive droplets 
were detected in 4 ml plasma equivalent DNA, with this criterion for a positive test 
being pre-defined. After taking account of the recovery of 43% of DNA present in 
plasma (as calculated above) the digital PCR assay would be anticipated to detect 
tumor specific mutations with 86% probability at an actual concentration of 2 
mutations per ml, and 99% probability at an actual concentration of 4 mutations per 
ml. The presence of increasing ctDNA abundance was defined as the doubling of 
mutant copies/ml from the nadir or the appearance of ctDNA when previously 
undetectable. Detection in baseline or post-surgery was defined as detection of 
ctDNA at the single timepoint. Mutation tracking was defined as detection of ctDNA 
in any of the post-surgical and serial ctDNA samples.  
 
Statistical analysis 
The primary endpoint of the study was to assess disease-free survival in 
patients with and without detection of ctDNA using univariable survival estimates 
calculated using the Kaplan-Meier method, and survival differences estimated using 
the log-rank test. Multivariable Cox regression analyses were used to test the 
independent prognostic value of mutation tracking and ctDNA, adjusted for tumor 
size, pathological nodal status and molecular subtypes respectively. Harrell’s C-index 
from the univariable and multivariable survival model was calculated (35). The C-
index is a probability of concordance between predicted and observed survival, 
defined as the probability that risk assignments to members of a random pair are 
accurately ranked according to their prognosis. C-index values of 0.5 indicate random 
prediction and higher values indicate increasing prediction accuracy. The associations 
of median ctDNA level with clinico-pathological markers were assessed using Mann-
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Whitney U test or Krustal-Wallis test where appropriate. The odds ratios of ctDNA 
detection with the standard clinicopathological variables were estimated using 
univariable logistic regression analysis. All statistical analysis was performed with 
GraphPad Prism version 6.0, or in R 3.0.1. with R packages survival, Hmisc, and rms. 
All p values are two sided. Disease-free survival, excluding contralateral invasive 
breast cancers, was assessed from the date of surgery. 
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Figure 1. Personalized digital PCR assays for mutation tracking of circulating 
tumor DNA in plasma of patients with early breast cancer. The baseline biopsy of 
patients presenting with early breast cancer was subjected to targeted massively 
parallel sequencing (MPS) to identify somatic (tumor-specific) mutations. 
Personalized, patient specific digital PCR (dPCR) assays were developed to detect the 
mutation in plasma DNA that was extracted from samples taken at baseline, post-
surgery, and serially every 6 months during follow-up (mutation tracking). After 
detection of circulating tumor DNA (ctDNA) with dPCR mutation tracking, plasma 
samples were subject to high-depth targeted capture MPS to interrogate the repertoire 
of somatic genetic alterations in detected minimal residual disease. MAF, mutant 
allele frequency. 
 
Figure 2. Personalized, mutation-specific dPCR accurately quantifies ctDNA and 
is highly reproducible. (A) Bland-Altman plot of the agreement between mutational 
frequency assessed by massively parallel sequencing (MPS) and by mutation-specific 
dPCR on baseline tumor DNA, with 95% CI of agreement -0.13 and 0.14 indicated by 
dashed lines. Data points from 55 mutation-specific dPCR assays are displayed. (B) 
Correlation of mutation abundance in repeat assays of mutation-specific dPCR assays 
in plasma DNA (Pearson’s correlation coefficient). Data from 17 mutation-specific 
assays in 9 different patients.  (C) Example of dPCR mutation tracking in two patients 
with early breast cancer, whose tumors harbored the same tumor PIK3CA c.3140A>T 
(p.H1047L) somatic mutation at the baseline plasma samples. The complete time 
course for patient A310001 is in fig. S1. In each dPCR plot, green dots represent 
wild-type DNA (VIC-labeled), blue dots represent mutant DNA (FAM-labeled), 
brown dots represent droplets containing both wild-type and mutant DNA, and black 
dots are droplets with no DNA incorporated.  
 
Figure 3. Early relapse is not predicted by analysis of baseline ctDNA. (A) 
Disease-free survival according to the detection of ctDNA in the baseline plasma 
sample. P value determined by log rank test). (B) Mutant copies per ml of plasma at 
baseline in patients who relapsed early and who did not relapse during follow up. P 
value determined by Mann Whitney U test. Data in (A and B) are from the same n = 
42 patients. ctDNA associations with other clinicopathological characteristics are in 
table S2. 
 
Figure 4.  Mutation tracking in serial plasma samples predicts early relapse. (A) 
Disease-free survival according to the detection of ctDNA in the first post-surgical 
plasma sample (HR 25.1 95% CI 4.08-130.5). P value determined by log rank test. 
Data are from n = 37 patients (B) Disease-free survival according to the detection of 
ctDNA in serial follow-up samples (HR 12.0 95% CI 3.36-43.07). P value determined 
by log rank test. Data are from n = 43 patients [37 of whom are represented in (A)]. 
 
 
Figure 5. Mutation-tracking in early-relapse and disease-free patients. (A) 
Mutation tracking profile in 26 patients who are currently disease-free after treatment 
of primary breast cancer. Mutations remain undetectable in the post-surgical and 
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follow-up periods in 25/26 patients. The remaining patient (A310033, red), with triple 
negative disease, had ctDNA detectable post-surgery with an increase in the 
detectable level of mutational load in follow-up sampling; however, this patient did 
not have clinical relapse at the time of reporting. (B) Mutation tracking detects 
ctDNA arising from minimal residual disease in patient A310004, with a lead-time of 
13.5 months over clinical relapse. Contrast-enhanced spiral CT scan revealed no 
abnormality at 14 months follow-up, although multiple liver metastases (white 
arrows) were subsequently detected at 19 months follow-up. M: months; PS: post-
surgery. (C) Mutation tracking ctDNA profiles prior to relapse, from 12 patients who 
experienced early relapse after treatment of primary breast cancer. After detecting 
ctDNA in a post-surgery or follow-up sample, ctDNA was detected in all subsequent 
samples prior to relapse. 
 
Figure 6.  Disease-free survival prediction based on single post-surgery ctDNA 
and mutation-tracking in serial plasma samples according to tumor subtype. (A) 
ER-positive breast cancers at first post-surgical sample (n=21) and serial follow-up 
samples (n=24). (B) ER-negative breast cancers at first post-surgical sample (n=16) 
and serial follow-up samples (n=19). (C) Triple-negative breast cancers (TNBC) at 
first post-surgical timepoint (n=11) and serial follow-up samples (n=13). P values 
determined by log rank test. 
 
 
Figure 7. High-depth targeted capture MPS of plasma DNA to characterize the 
genomic landscape of minimal residual disease. For five patients, DNA was 
extracted from microdissected primary tumor, residual tumor post-chemotherapy 
removed at surgery, metastatic tumor biopsies where available, plasma DNA samples 
and germline lymphocyte DNA and subjected to targeted capture massively parallel 
sequencing using a custom panel targeting the exons of 273 genes recurrently mutated 
in breast cancer or involved in DNA repair pathways. Two patients are provided in fig. 
S2. (A)  (Left) High-depth targeted capture MPS in patient A310003 of baseline 
primary tumor biopsy, two separate surgery samples post-chemotherapy, plasma 
DNA samples at 17 and 8 months pre-relapse, and metastatic disease biopsy taken on 
subsequent relapse. (Right) Validation of MPS findings with dPCR and Sanger 
sequencing. The FGFR1 mutation is detectable at a low level 17 months prior to 
relapse. A diagram illustrates possible clonal selection in this patient through therapy 
and time. Immunohistochemistry of baseline and metastatic tumor samples are in fig. 
S5A. (B) High-depth targeted capture MPS in patient A310035 of baseline primary 
tumor biopsy, plasma DNA before relapse, relapse biopsy, and plasma DNA 
following relapse. Analysis of surgery sample is shown in figure S5B. (C) High-depth 
targeted capture MPS in patient A310004 of baseline primary tumor biopsy, plasma 
DNA 6.1 months pre-relapse and relapse biopsy (Left). Relapse biopsy revealed a 
RB1 c.958C>T (R320*) somatic mutation that was not detectable by sequencing of 
the plasma. (Right) Validation of MPS findings with digital PCR. RB1 mutation was a 
late arising event, that was not detectable 6.1 months prior to relapse, but then rose to 
relative clonal abundance at relapse (p<0.0001, chi-square test for trend). There was a 
pathological complete response to chemotherapy in the primary tumor. M: months; 
MAF: mutant allele frequency 
MPS tumor sequencing to 
identify mutation
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Figure S1. Mutation tracking by dPCR along a 24-month follow-up of a disease-
free patient. Complete series of digital PCR plots in chronological order for case 
A310001 (in Fig. 2C), tracking a PIK3CA c.3140A>T (p.H1047L) mutation. In each 
plot, green dots represent VIC-labeled wild-type DNA and blue dots represent FAM-
labeled mutant DNA. Brown dots represent droplets containing both wild-type and 















Figure S2. High-depth targeted capture massive parallel sequencing on plasma 
DNA from two relapsed patients. High-depth targeted capture MPS of primary 
tumor DNA and plasma DNA in two patients who relapsed with detectable ctDNA 
levels. Displayed are genes with somatic mutations called by at least two variant 
callers in one sample (see Methods). In A310006, insufficient DNA was available 
from the primary cancer, although plasma DNA sequencing revealed no additional 
mutations other than the PIK3CA mutation known to be present in the primary by 
AmpliSeq PGM sequencing. In A310012, plasma DNA sequencing revealed 
substantial divergence of the genetics of the ctDNA arising from RMD compared to 





Figure S3. Copy number profile in primary tumor and plasma DNA prior to 
relapse. Exploratory copy number analysis of high depth capture MPS of ctDNA 
arising from micro-metastatic disease. Copy number profiles were derived from 
primary tumor and corresponding plasma DNA samples. Regions of copy number 
gain are in green, loss in red, neutral in black. The chromosomes are arranged in order 
from left to right, with red lines demarcating the chromosomes and grey lines 
demarcating the chromosome arms. (A) In known amplified A310004, HER2 
amplification was detected in plasma DNA sequencing. Tumor purity in plasma DNA 
at 12 months was estimated as 9.3%, from frequency of ANK3 and TP53 mutations 
present, assuming heterozygosity and diploid, with the ability to detect HER2 
amplification reflecting the likely high level HER2 copy number. (B) In A310012 
MDM2 amplification was detected in both primary and plasma DNA. Tumor purity in 
plasma DNA was estimated to be 26%. No copy number events were detectable in 





Figure S4. Validation and follow-up of MPS on plasma DNA. MPS data for these 
three patients are shown in Fig. 7. (A) ER immunohistochemistry staining in patient 
A310003 at baseline and relapsed disease. (B) Investigation of clonal selection in 
patient A310035 using dPCR. The SYNE1 mutation was below the level of 
discrimination in the baseline tumor, detected only at a level consistent with formalin 
fixation artifact, but was enriched in the post-chemotherapy resection specimen, and 
in subsequent follow-up plasma samples. (C) Multiplex dPCR assay used to detect 
three different mutations in plasma from patient A310004: ANK3 c.3247G>C, XIRP2 
c.3473delA, and RB1 c.958C>T. Representative plots are shown for analysis of DNA 



































































PIK3CA c.1035T>A CCCTTTGGGTTATAAATAGTGCACTCA AGCATCAGCATTTGACTTTACCTTATCA AACCTACGTGAATGTAAATA VIC NFQMGB CCTACGTGAAAGTAAATA 6-FAM NFQMGB 63 103 NG_012113.2 
A310018 
PIK3CA c.1258T>C AAAAGTGTTTTGAAATGTGTTTTATAATTTAGACTAGTGA CAGATACTAGAGTGTCTGTGTAATCAAACA CAATGGACAGTGTTCC VIC NFQMGB AATGGACGGTGTTCC 6-FAM NFQMGB 60 126 NG_012113.2 
A310045, A310048 
PIK3CA c.1624G>A GCTCAAAGCAATTTCTACACG TCCATTTTAGCACTTACCTGTGAC TCTCTGAAATCACTGAGCAGGAGAA VIC NFQMGB TCTCTAAAATCACTGAGCAGGAGAA 6-FAM NFQMGB 63 90 NG_012113.2 
A310040, A310047, A310054 
PIK3CA c.1633G>A GCTCAAAGCAATTTCTACACG TCCATTTTAGCACTTACCTGTGAC TCTCTGAAATCACTGAGCAGGAGAA VIC NFQMGB TCTCTGAAATCACTAAGCAGGAGAA 6-FAM NFQMGB 63 90 NG_012113.2 
A310005 
PIK3CA c.1636C>A TCAAAGCAATTTCTACACGAGATCCT CTCCATTTTAGCACTTACCTGTGACT AAATCTTTCTCCTGCTCAGTG VIC NFQMGB AAAATCTTTCTCCTTCTCAGTG 6-FAM NFQMGB 60 91 NG_012113.2 
A310001, A310006 
PIK3CA c.3140A>T TGAGCAAGAGGCTTTGGAGT TCAGTTCAATGCATGCTGTTT AATGATGCACATCATGGTGGCT VIC NFQMGB AATGATGCACTTCATGGTGGCT 6-FAM NFQMGB 61.7 115 NG_012113.2 
A310003, A310012, A310017, A310021 
PIK3CA c.3140A>G TGAGCAAGAGGCTTTGGAGT TCAGTTCAATGCATGCTGTTT AATGATGCACATCATGGTGGCT VIC NFQMGB AATGATGCACGTCATGGTGGCT 6-FAM NFQMGB 61.7 115 NG_012113.2 
A310034 
TP53 c.267_268delC GCACCAGCAGCTCCTACAC TGGGAAGGGACAGAAGATGACA CCAGCCCCCTCCTGG VIC NFQMGB ACCAGCCCCTCCTGG 6-FAM NFQMGB 60 72 NG_017013.2 
A310037 
TP53 c.321C>A TCCCTTCCCAGAAAACCTACCA GCTGTCCCAGAATGCAAGAAG CGGAAACCGTAGCTGC VIC NFQMGB ACGGAAACCTTAGCTGC 6-FAM NFQMGB 60 66 NG_017013.2 
A310007 
TP53 c.394A>G GTCTCCTTCCTCTTCCTACAGTACT GCAGGTCTTGGCCAGTTG CCCTCAACAAGATGTT VIC NFQMGB CCTCAACGAGATGTT 6-FAM NFQMGB 60 69 NG_017013.2 
A310016 
TP53 c.396G>C GTCTCCTTCCTCTTCCTACAGTACT GCAGGTCTTGGCCAGTTG CCCTCAACAAGATGTTTT VIC NFQMGB CCTCAACAACATGTTTT 6-FAM NFQMGB 60 69 NG_017013.2 
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A310017 
TP53 c.398T>A GTCTCCTTCCTCTTCCTACAGTACT GCAGGTCTTGGCCAGTTG CCTCAACAAGATGTTTTG VIC NFQMGB CTCAACAAGAAGTTTTG 6-FAM NFQMGB 60 69 NG_017013.2 
A310026 
TP53 c.451C>G GCCCTGTGCAGCTGTG CATGGCGCGGACGC TTGATTCCACACCCCCGC VIC NFQMGB ATTCCACAGCCCCGC 6-FAM NFQMGB 60 59 NG_017013.2 
A310039, A310045 
TP53 c.452C>A TGTGCAGCTGTGGGTTGAT CATGGCGCGGACGC TCCACACCCCCGCCC VIC NFQMGB CCACACACCCGCCC 6-FAM NFQMGB 56 54 NG_017013.2 
A310013 
TP53 c.477_478delC TGGGTTGATTCCACACCCC ATGTGCTGTGACTGCTTGTAGA CGCGCATGGCCA VIC NFQMGB CGCGCATGGCCA 6-FAM NFQMGB 60 69 NG_017013.2 
A310012 
TP53 c.503A>C GCGCCATGGCCATCTACA GGCAGCGCCTCACAAC AGTCACAGCACATGAC VIC NFQMGB CAGTCACAGCCCATGAC 6-FAM NFQMGB 60 57 NG_017013.2 
A310030, A310038, A310043, A310053 
TP53 c.524G>A ACAGCACATGACGGAGGTT CTGCTCACCATCGCTATCTGA TGAGGCGCTGCCC VIC NFQMGB TGAGGCACTGCCC 6-FAM NFQMGB 52 70 NG_017013.2 
A310024 
TP53 c.528C>A AGCACATGACGGAGGTTGT CTGCTCACCATCGCTATCTGA AGGCGCTGCCCCCA VIC NFQMGB AGGCGCTGACCCCA 6-FAM NFQMGB 60 68 NG_017013.2 
A310011 
TP53 c.537T>A AGCACATGACGGAGGTTGT CTGCTCACCATCGCTATCTGA CCCACCATGAGCGCT VIC NFQMGB CCACCAAGAGCGCT 6-FAM NFQMGB 60 68 NG_017013.2 
A310015 
TP53 c.586C>T TGGCCCCTCCTCAGCAT CATCCAAATACTCCACACGCAAATT CCTTCCACTCGGATAAG VIC NFQMGB CCTTCCACTCAGATAAG 6-FAM NFQMGB 60 60 NG_017013.2 
A310021 
TP53 c.712T>G CTGACTGTACCACCATCCACTAC ATGGGCCTCCGGTTCATG CAGGAACTGTTACACATGTA VIC NFQMGB CAGGAACTGTTACCCATGTA 6-FAM NFQMGB 60 74 NG_017013.2 
A310046 
TP53 c.713G>T TGGCTCTGACTGTACCACCAT GATGGGCCTCCGGTTCAT ACAACTACATGTGGTAACAG VIC NFQMGB ACAACTACATGTTGTAACAG 6-FAM NFQMGB 60 72 NG_017013.2 
A310033 
TP53 c.742C>T AACTACATGTGTAACAGTTCCTGCAT GAGTCTTCCAGTGTGATGATGGT TGGGCCTCCGGTTCA VIC NFQMGB TGGGCCTCCAGTTCA 6-FAM NFQMGB 60 77 NG_017013.2 
A310043 
TP53 c.743G>A AACTACATGTGTAACAGTTCCTGCAT CCAGTGTGATGATGGTGAGGAT CATGAACCGGAGGCC VIC NFQMGB CATGAACCAGAGGCC 6-FAM NFQMGB 60 70 NG_017013.2 
A310055 
TP53 c.796G>C CCTCTTGCTTCTCTTTTCCTATCCT CCAGGACAGGCACAAACAC AAGCTGTTCCGTCCCAGTAG VIC NFQMGB CTGTTCCGTCGCAGTAG 6-FAM NFQMGB 60 73 NG_017013.2 
A310027 
TP53 c.801_802delG CCTCTTGCTTCTCTTTTCCTATCCT CCAGGACAGGCACAAACAC CAAAGCTGTTCCGTCCC VIC NFQMGB CAAAGCTGTTCGTCCC 6-FAM NFQMGB 60 84 NG_017013.2 
A310004 
TP53 c.824G>T TGGGACGGAACAGCTTTGAG CTGTGCGCCGGTCTCT GCGTGTTTGTGCCTG VIC NFQMGB TGCGTGTTTTTGCCTG 6-FAM NFQMGB 60 60 NG_017013.2 
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A310001 
TP53 c.832C>G AGCTTTGAGGTGCGTGTTTG TGCGGAGATTCTCTTCCTCTGT TCTCCCAGGACAGGCA VIC NFQMGB CTCCCAGCACAGGCA 6-FAM NFQMGB 60 67 NG_017013.2 
A310031 
TP53 c.841G>C GCTTTGAGGTGCGTGTTTGTG TGCGGAGATTCTCTTCCTCTGT CCTGGGAGAGACCG VIC NFQMGB CCTGGGAGACACCG 6-FAM NFQMGB 60 67 NG_017013.2 
A310025 
TP53 c.853G>A TGCCTGTCCTGGGAGAGA GGTGAGGCTCCCCTTTCTTG CGCACAGAGGAAGAG VIC NFQMGB CGCACAAAGGAAGAG 6-FAM NFQMGB 58 67 NG_017013.2 
A310004 




TCTATGACCCCAGAGAACTTCGT TCATGCCCCACTTGATTTCGTA AGCAGACAGGCCTCTT VIC NFQMGB AGCAGACAGACCTCTT 6-FAM NFQMGB 60 62 NC_000072.6 
A310014 
CDH1 c.1946_1947insT 
CTCCCCTGGTCTCATCATTTCTTTT CCACCTCTAAGGCCATCTTTGG CAGCCCAAGAATCTATCAT VIC NFQMGB AGCCCAAGAATCTTATCAT 6-FAM NFQMGB 60 86 NG_008021.1 
A310010 
CDH1 c.830G>A CCCCCTGTTGGTGTCTTTATTATTGA TGGCAATGCGTTCTCTATCCA ACCTTCAGCCATCCTG VIC NFQMGB CACCTTCAGTCATCCTG 6-FAM NFQMGB 60 82 NG_008021.1 
A310036 
ERBB2 c.929C>A GGCTACATGTTCCTGATCTCCTTAG TGCTGTCACCTCTTGGTTGTG ACGTGGGATCCTGCACC VIC NFQMGB CGTGGGATACTGCACC 6-FAM NFQMGB 60 95 NG_007503.1 
A310003 
ESR1 c.1138G>C GCTTTGTGGATTTGACCCT AGTAGCTTCCCTGGGTGC TCTAGAATGTGCCTGGCTAGAGATC VIC NFQMGB TCTACAATGTGCCTGGCTAGAGATC 6-FAM NFQMGB 61.7 112 NG_008493.1 
A310003 
FGFR1 c.1966A>G GGGACATTCACCACATCGACTAC ACAGGGCGGCCTTGTC ACGTTGGTTGTCTTTTTATA VIC NFQMGB CGTTGGTTGTCTCTTTATA 6-FAM NFQMGB 60 66 NG_007729.1 
A310051 
GATA3 c.1002_1003delGG 
GACCACCACAACCACACTCT AGCCCACAGGCATTGCA AGGGTCCCCATTGGCAT VIC NFQMGB CAGGGTCCATTGGCAT 6-FAM NFQMGB 60 63 NG_015859.1 
A310023 
GATA3 c.1667_1670delCGAAA 
GACTATGAAGAAGGAAGGCATCCA CCTCCAGTGAGTCATGCACTTTT CTAGACATTTTTCGGTTTCT VIC NFQMGB TTGCTAGACATTGTTTCT 6-FAM NFQMGB 58 84 NG_015859.1 
A310023 
GATA3 c.1672A>T GGAAGGCATCCAGACCAGAAAC CCTCCAGTGAGTCATGCACTTTT TGCTAGACATTTTTCG VIC NFQMGB TGCTAGACATATTTCG 6-FAM NFQMGB 60 77 NG_015859.1 
A310041 
GATA3 c.991_993insG CAGACCACCACAACCACACT CCCACAGGCATTGCAGACA CATTGGCATTCCTCCTCCA VIC NFQMGB TGGCATTCCCTCCTCCA 6-FAM NFQMGB 60 66 NG_015859.1 
A310020 
KMT2C (MLL3) c.2670_2671delT 
TGTTGACTTTTCCCAATCTGTTACATAGG CCTCGCCCCGACAGT TTTCCTGGAAATCCAG VIC NFQMGB TTTCCTGGAATCCAG 6-FAM NFQMGB 60 88 NG_033948.1  
A310004 
RB1 c.958C>T GTCAGTGACTTTTTTCTTTCAAGGTTGA CATGATCCAAAAATAATCTTGCATCTAGATCT AAATTTCTTCGTATCGTTTAGAA VIC NFQMGB AAATTTCTTCGTATCATTTAGAA 6-FAM NFQMGB 60 103 NG_009009.1 
A310035 
SYNE-1 c.3731C>A GGGACTGTGTCCAGTACAAAGAAAT AGCTTGTTCCTGGACTTCTTTAGAG TCTTCGAGAGAATTTT VIC NFQMGB TTCTTCGAGATAATTTT 6-FAM NFQMGB 60 82 NG_012855.1 
A310036 
SYNE-1 c.4065C>G GGGAGCGATTTGAAACAAACAAAGA CTGCTAAAACTCAAGAAGCGTTCAT CTGTTTGAAAAAGGTATCTT VIC NFQMGB CTGTTTGAAAAAGCTATCTT 6-FAM NFQMGB 60 87 NG_012855.1 
 9 
A310037 
TBX3 c.1817C>T CCCCTTTCGGAAGCCTGTTC GGCTGCCGCAGAGGAG ACCCCTACACGTACATG VIC NFQMGB TTACCCCTACATGTACATG 6-FAM NFQMGB 60 73 NG_008315.1 
A310004 















































Table S2. Clinicopathological factors associated with baseline ctDNA level. P 
values for median ctDNA levels were determined using Kruskal-Wallis rank sum test. 
P values for the percentage of ctDNA were determined using Chi-square test. Clinical 
tumor size: T1/2 < 50 mm versus T3/4 ≥ 50 mm or locally advanced at presentation. 
Clinical node positive: cytologically confirmed lymph node involvement at 
presentation. ER, estrogen receptor expression by immunohistochemistry. HER2 
status: HER2+ by immunohistochemistry or in situ hybridization. TNBC, triple 
negative breast cancer (negative for ER, HER, and progesterone receptor). 
Subsequent pCR: subsequent achievement of pathological complete response.  
 
  Median ctDNA 
level copies per ml 




Clinical tumor size       T1/2 3.878 0.42 64 0.42  T3/4 4.964  77  
Clinical node 
positive 
    Yes 5.514 0.11 86 0.015 No 0.615  50  
Histological grade     3 5.947 0.03 79 0.015 2 0  42  
ER status     Positive 1.597 0.011 54 0.016 Negative 14.61  89  
HER2 status     Positive 5.355 0.88 71 1 Negative 3.72  68  
Subtype     TNBC 15.95 0.027 92 0.033 HER2+ 5.355  71  ER+HER2– 0  47  






Table S3. Prediction of disease free survival using a single post-surgery blood 
sample. A multivariable Cox model was applied, adjusting for clinicopathological 
factors including molecular subtypes, clinical tumor size and pathological lymph 
nodal status. Clinical tumor size was the size of tumor at presentation (T1/2 vs T3/4). 
Macrometastases on axillary surgery/sentinel node were evaluated after neoadjuvant 
chemotherapy vs pathological (n = 36). One patient was excluded due to missing data. 
The Cox model had a C-index of 0.795. 
 
Covariates Multivariable Cox regression model  P 
value   HR 95% CI 
ctDNA detection post-surgery    
Yes vs. No 21.1 2.5-177.47 0.005 
Subtypes    
TNBC vs. HER2+ vs. 
ER+/HER2– 
1.3 0.56-3.0 0.55 
Clinical tumor size     
T3/4 vs. T1/2 0.79 0.13-4.9 0.8 
Pathological node–positive 
post-chemo 
   

















Table S4. Prediction of disease-free survival by mutation-tracking using serial 
blood samples. A multivariable Cox model was applied, adjusting for 
clinicopathological factors including molecular subtypes, clinical tumor size, and 
lymph nodal status. Clinical tumor size was the size of tumor at presentation (T1/2 vs 
T3/4 Macrometastases on axillary surgery/sentinel node were evaluated after 
neoadjuvant chemotherapy vs pathological (n = 42). One patient was excluded due to 
missing data. The Cox model had a C-index of 0.802.  
Covariates Multivariable Cox 
Regression model 
  
  HR 95% CI p 
value 
Mutation Tracking       
Yes vs. No 9.6 2.4-38.9 0.001 
Subtypes       
Triple negative subtype vs. HER2+ vs 
ER+/HER2- 
1.6 0.82-3.0 0.17 
Clinical tumor size        
T3/4 vs T1/2 1.3 0.42-4.1 0.64 
Pathological node positive post 
chemo 
      

























Table S5. Summary of the study cohort. Summary of the study cohort, illustrating 
the distribution of the main clinico-pathological factors in overall population, disease-
free and early relapse groups. Abbreviations: cT, clinical tumor size; ER, estrogen 
receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal 
carcinoma; ILC, invasive lobular carcinoma; mo, months; N/A, not available; NAC, 
neoadjuvant chemotherapy; NST, non-special type; PgR, progesterone receptor; 
pathCR, pathological complete response; y, years. pathCR, pathological complete 
response indicating absence of residual invasive cancer in breast and axillary lymph 
nodes. 
 
 All patients (%) Disease free (%) Relapse (%) 
N 55 40 (73) 15 (27) 
    
Median age (range), y 50 (25–76) 50 (25–76) 50 (32–65) 
    
Pathology    
IDC 43 (78) 33 (82.5) 10 (66.5) 
ILC 4 (7) 4 (10) 0 (0) 
Mixed IDC/ILC 6 (11) 2 (5) 4 (27) 
Metaplastic 1 (2) 1 (2.5) 0 (0) 
Neuroendocrine 1 (2) 0 (0) 1 (6.5) 
    
Histologic grade    
1 0 (0) 0 (0) 0 (0) 
2 17 (31) 13 (32.5) 4 (27) 
3  37 (67) 26 (65) 11 (73) 
N/A 1 (2) 1 (2.5) 0 (0) 
    
Receptor status    
ER/PgR+ HER2- 20 (36.5) 16 (40) 4 (27) 
ER/PgR- HER2+ 8 (14.5) 7 (17.5) 1 (6) 
ER/PgR+ HER2+ 13 (23.5) 9 (22.5) 4 (27) 
Triple negative 14 (25.5) 8 (20) 6 (40) 
    
Clinical size at presentation (cT)    
1 6 (11) 6 (15) 0 (0) 
2 33 (60) 25 (62.5) 8 (53.5) 
3 5 (9) 3 (7.5) 2 (13) 
4 10 (18) 5 (12.5) 5 (33.5) 
N/A 1 (2) 1 (2.5) 0 (0) 
    
Nodal status at presentation    
Negative 27 (49) 22 (55) 5 (33.5) 
Positive 28 (51) 18 (45) 10 (66.5) 
    
Pathological response to NAC    
No pathCR 41 (74.5) 29 (72.5) 12 (80) 
pathCR 13 (23.5) 10 (25) 3 (20) 
N/A 1 (2) 1 (2.5) 0 (0) 
    
Median follow-up (mo)    
From study entry 21.4 20.8 24.8 




Table S6. Ion AmpliSeq Breast Cancer driver gene panel. 
 
AKT1 ex4 MAP3K1 
BRAF ex15 PIK3CA ex5, 8, 
9, 20 
CDH1 PIK3R1 ex4, 6 
GATA3 PTEN 
KIT ex11 RUNX1 ex1, 2, 3 
KRAS ex2 SF3B1 ex14, 15 
MAP2K4 TP53 ex5, 6, 7, 8 
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Table S7: Reads from capture MPS of tumor and plasma DNA. Chr, 
chromosome; AA, aminoacid; Ref, reference nucleotide; Alt, alternative nucleotide; 








Effect AA Gene Chr POS REF ALT 
A310003 Tumor Primary 23 107 NON_SYNONYMOUS_CODING D455N AKT3 1 243668628 C T A310003 Tumor Primary 61 101 NON_SYNONYMOUS_CODING H1047R PIK3CA 3 178952085 A G A310003 Tumor Primary 47 233 NON_SYNONYMOUS_CODING V51I PDGFRB 5 149515331 C T A310003 Tumor Primary 35 104 NON_SYNONYMOUS_CODING A3244V MDN1 6 90405364 G A A310003 Tumor Primary 8 130 NON_SYNONYMOUS_CODING P457L TBX3 12 115112370 G A A310003 Tumor Primary 6 58 NON_SYNONYMOUS_CODING I3329T APOB 2 21229754 A G A310003 Tumor Primary 8 54 NON_SYNONYMOUS_CODING E380Q ESR1 6 152332832 G C A310003 Tumor Primary 13 234 NON_SYNONYMOUS_CODING G1357A PLEC 8 145001675 C G A310003 Tumor Surgery 1 24 130 NON_SYNONYMOUS_CODING H1047R PIK3CA 3 178952085 A G A310003 Tumor Surgery 1 8 105 NON_SYNONYMOUS_CODING I3329T APOB 2 21229754 A G A310003 Tumor Surgery 1 14 113 NON_SYNONYMOUS_CODING E380Q ESR1 6 152332832 G C A310003 Tumor Surgery 1 5 128 NON_SYNONYMOUS_CODING D455N AKT3 1 243668628 C T A310003 Tumor Surgery 2 28 147 NON_SYNONYMOUS_CODING H1047R PIK3CA 3 178952085 A G A310003 Tumor Surgery 2 9 110 NON_SYNONYMOUS_CODING D455N AKT3 1 243668628 C T A310003 Tumor 12 123 NON_SYNONYMOUS E380 ESR1 6 152332832 G C 
 16 
Surgery 2 _CODING Q A310003 Tumor Surgery 2 4 109 NON_SYNONYMOUS_CODING I3329T APOB 2 21229754 A G A310003 cfDNA 8 months pre-relapse 
6 239 NON_SYNONYMOUS_CODING K687E FGFR1 8 38272308 T C 
A310003 cfDNA 8 months pre-relapse 
9 231 NON_SYNONYMOUS_CODING H1047R PIK3CA 3 178952085 A G 
A310003 Tumor Metastatic 52 113 NON_SYNONYMOUS_CODING G1809D FLG 1 152281936 C T A310003 Tumor Metastatic 378 499 NON_SYNONYMOUS_CODING H1047R PIK3CA 3 178952085 A G A310003 Tumor Metastatic 315 704 NON_SYNONYMOUS_CODING K687E FGFR1 8 38272308 T C A310035 Tumor Primary 2 400 FRAME_SHIFT S402fs GATA3 10 8115855 TCCTCCCTGAGCCACATCTCG 
T 
A310035 Tumor Primary 46 200 NON_SYNONYMOUS_CODING A36V APOBEC1 12 7805369 G A A310035 Tumor Primary 7 237 NON_SYNONYMOUS_CODING K177R STAT3 17 40490769 T C A310035 cfDNA pre-relapse 39 389 NON_SYNONYMOUS_CODING A36V APOBEC1 12 7805369 G A A310035 cfDNA pre-relapse 13 335 NON_SYNONYMOUS_CODING S1244Y SYNE1 6 152765652 G T A310035 cfDNA pre-relapse 3 417 FRAME_SHIFT S402fs GATA3 10 8115855 TCCTCCCTGAGCCACATCTCG 
T 
A310035 cfDNA pre-relapse 2 569 NON_SYNONYMOUS_CODING K177R STAT3 17 40490769 T C A310035 94 277 NON_SYN A3 APOBE 12 78053 G A 
 17 
Tumor Metastatic ONYMOUS_CODING 6V C1 69 A310035 Tumor Metastatic 10 59 NON_SYNONYMOUS_CODING S1244Y SYNE1 6 152765652 G T A310035 Tumor Metastatic 36 520 FRAME_SHIFT S402fs GATA3 10 8115855 TCCTCCCTGAGCCACATCTCG 
T 
A310035 cfDNA post-relapse 
86 393 NON_SYNONYMOUS_CODING A36V APOBEC1 12 7805369 G A A310035 cfDNA post-relapse 
63 494 NON_SYNONYMOUS_CODING S1244Y SYNE1 6 152765652 G T A310035 cfDNA post-relapse 
26 461 FRAME_SHIFT S402fs GATA3 10 8115855 TCCTCCCTGAGCCACATCTCG 
T 
A310004 Tumor Primary 20 39 NON_SYNONYMOUS_CODING E1083Q ANK3 10 61865744 C G A310004 Tumor Primary 8 14 NON_SYNONYMOUS_CODING C275F TP53 17 7577114 C A A310004 Tumor Primary 3 23 FRAME_SHIFT Q1158fs XIRP2 2 168101374 CA C A310004 cfDNA 6.1 months pre-relapse 
19 315 NON_SYNONYMOUS_CODING E1083Q ANK3 10 61865744 C G 
A310004 cfDNA 6.1 months pre-relapse 
9 272 NON_SYNONYMOUS_CODING C275F TP53 17 7577114 C A 
A310004 cfDNA 6.1 months pre-relapse 
4 258 FRAME_SHIFT Q1158fs XIRP2 2 168101374 CA C 
A310004 Tumor 94 127 NON_SYNONYMOUS E108 ANK3 10 61865744 C G 
 18 
Metastatic _CODING 3Q A310004 Tumor Metastatic 49 100 STOP_GAINED R320* RB1 13 48941648 C T A310004 Tumor Metastatic 302 382 NON_SYNONYMOUS_CODING C275F TP53 17 7577114 C A A310004 Tumor Metastatic 11 384 STOP_GAINED S33* USH2A 1 216595581 G C A310004 Tumor Metastatic 53 149 FRAME_SHIFT Q1158fs XIRP2 2 168101374 CA C A310006 cfDNA 2 months pre-relapse 
11 321 NON_SYNONYMOUS_CODING H1047L PIK3CA 3 178952085 A T 
A310012 Tumor Primary 25 137 NON_SYNONYMOUS_CODING S1002C FLG 1 152284357 G C A310012 Tumor Primary 22 112 STOP_GAINED Q5513* KMT2D 12 49415640 G A A310012 Tumor Primary 18 71 STOP_GAINED Q543* NF1 17 29546122 C T A310012 Tumor Primary 18 101 STOP_GAINED E362* PRKCA 17 64731634 G T A310012 Tumor Primary 29 138 NON_SYNONYMOUS_CODING I1508M 
CACNA
1A 
19 13368242 G C 
A310012 Tumor Primary 26 138 NON_SYNONYMOUS_CODING E276K CACNA1A 19 13470572 C T A310012 Tumor Primary 14 86 NON_SYNONYMOUS_CODING D1913N TENM1 X 123519866 C T A310012 Tumor Primary 7 128 NON_SYNONYMOUS_CODING S1973C CACNA1C 12 2794997 C G A310012 Tumor Primary 6 164 NON_SYNONYMOUS_CODING S758C VWF 12 6155897 G C A310012 Tumor Primary 18 130 NON_SYNONYMOUS_CODING H5459Y KMT2D 12 49416100 G A A310012 Tumor Primary 13 115 NON_SYNONYMOUS_CODING L578V SRCAP 16 30723395 C G A310012 21 108 NON_SYN H1 TP53 17 75784 T G 
 19 
Tumor Primary ONYMOUS_CODING 68P 27 A310012 Tumor Primary 11 123 NON_SYNONYMOUS_CODING F20L PRKCA 17 64299029 C G A310012 Tumor Primary 14 142 NON_SYNONYMOUS_CODING S111C ERCC2 19 45871916 G C A310012 Tumor Primary 7 93 NON_SYNONYMOUS_CODING S37L BIRC6 2 32582339 C T A310012 Tumor Primary 8 62 NON_SYNONYMOUS_CODING Q631H CHD6 20 40116413 C G A310012 Tumor Primary 7 53 NON_SYNONYMOUS_CODING H1047R PIK3CA 3 178952085 A G A310012 Tumor Primary 7 96 NON_SYNONYMOUS_CODING D3988H SYNE1 6 152668310 C G A310012 Tumor Primary 15 91 STOP_GAINED E3738* KMT2C 7 151859450 C A A310012 Tumor Primary 8 128 NON_SYNONYMOUS_CODING R1402C TENM1 X 123556389 G A A310012 cfDNA 6 months pre-relapse 
36 281 STOP_GAINED Q5513* KMT2D 12 49415640 G A 
A310012 cfDNA 6 months pre-relapse 
55 328 STOP_GAINED Q543* NF1 17 29546122 C T 
A310012 cfDNA 6 months pre-relapse 
83 343 STOP_GAINED E362* PRKCA 17 64731634 G T 
A310012 cfDNA 6 months pre-relapse 
50 302 NON_SYNONYMOUS_CODING E3859Q KMT2C 7 151856043 C G 
A310012 cfDNA 6 months pre-relapse 
39 274 NON_SYNONYMOUS_CODING R1402C TENM1 X 123556389 G A 
A310012 cfDNA 6 31 254 NON_SYNONYMOUS H545 KMT2D 12 49416100 G A 
 20 
months pre-relapse _CODING 9Y A310012 cfDNA 6 months pre-relapse 
42 306 NON_SYNONYMOUS_CODING M1561I 
FANCM 14 45656994 G C 
A310012 cfDNA 6 months pre-relapse 
27 254 NON_SYNONYMOUS_CODING H168P TP53 17 7578427 T G 
A310012 cfDNA 6 months pre-relapse 
38 325 NON_SYNONYMOUS_CODING Q631H CHD6 20 40116413 C G 
A310012 cfDNA 6 months pre-relapse 
43 329 NON_SYNONYMOUS_CODING H1047R PIK3CA 3 178952085 A G 
A310012 cfDNA 6 months pre-relapse 
33 294 STOP_GAINED E3738* KMT2C 7 151859450 C A 
A310012 cfDNA 6 months pre-relapse 
35 321 STOP_GAINED E1260* KMT2C 7 151904448 C A 
A310012 cfDNA 6 months pre-relapse 
37 303 NON_SYNONYMOUS_CODING G45E PKHD1L1 8 110376836 G A 
A310012 cfDNA 6 months pre-relapse 
11 160 NON_SYNONYMOUS_CODING S3143C PLEC 8 144994972 G C 
 
